2019 MSK Cardio-Oncology Symposium
2019 MSK Cardio-Oncology Symposium is organized by Memorial Sloan Kettering Cancer Center (MSKCC) and will be held from May 17 - 18, 2019 at Rockefeller Research Laboratories, New York City, New York, United States of America.
The target audience for this medical event is intended for cardiologists, internists, hematologists/oncologists and other affiliated healthcare professionals who are involved in the care of cancer patients or have a special interest in this area.This Conference has been approved for a maximum of 16.25 AMA PRA Category 1 Credits™.
ABIM MOC Recognition Statement:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 16.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Cardio-oncology is a burgeoning field that has great importance as newly developed cancer treatment improve cancer survival. With a novel, treatments come new or unexpected cardiovascular toxicities as many cancer survivors are now living enough to experience the potential cardiotoxic effects of these treatments.
The purpose of this conference is to provide a state-of-the-art, comprehensive, case-based curriculum that addresses important clinical topics relevant to the cardiovascular health of patients with cancer. Clinical experts from Memorial Sloan Kettering Cancer Center and around the country will present an up-to-date overview on cutting-edge cancer therapies and best practice strategies in the evaluation and management of heart disease in cancer patients from early diagnosis, treatment, and long-term surveillance. All presentations will include devoted time to permit interaction between audience members and presenters.
• Describe the cardiotoxic regimens used in cancer treatment including novel targeted therapies
• Identify patients at high cardiovascular risk prior to planned oncologic treatment
• Construct cardioprotective strategies prior, during and after cancer therapy
• Explain the principles of surveillance and the incorporation of current guidelines on cardiotoxicity monitoring into clinical practice.
• Describe primary and secondary prevention of cardiotoxicity
• Explain the appropriate use of non-invasive imaging modalities for cardiotoxicity monitoring; the strengths and weaknesses of each modality including echocardiography, MUGA, CMR and CTA.
• State the late cardiovascular sequelae of cancer and its treatment
• Describe the importance of the multi-disciplinary cardio-oncology team
|Contact No. :||646-227-2025
|Registration Type||End Date||Price|
|Physicians (MDs, PhDs and DOs) General Fee||16 May,2019||USD 525.00|
|Industry Professionals General Fee||16 May,2019||USD 925.00|
|Residents, Fellows Fee, Nurses and Other Healthcare Professionals General Fee||16 May,2019||USD 350.00|